Rohto and Mitsui lead acquisition of Eu Yan Sang for $695M

The Japanese companies acquired an 86% stake in the company.

A consortium led by Japanese companies Rohto Pharmaceutical and Mitsui & Co. has acquired Singapore-based traditional Chinese medicine company Eu Yan Sang International (EYSI) for $695m.

The consortium acquired an 86% stake from Righteous Crane Holding (RCH).

RCH is an investment holding company owned by Tower Capital Asia subsidiary, Tower Capital TCM Holdings, and Temasek Holdings unit Blanca Investments.

“In 2016, we chose to partner with Tower Capital Asia due to their understanding of the Eu Yan Sang heritage and commitment to driving excellence. Tower Capital Asia, together with Temasek, was instrumental in elevating the EYSI brand, institutionalising operations, and establishing the foundation for our next chapter as a natural health and wellness brand,"  said Richard Eu, chairman of EYSI.